logo
Once-booming Texas border city known for affordability loses appeal among homebuyers

Once-booming Texas border city known for affordability loses appeal among homebuyers

New York Post15-07-2025
Long recognized for its affordable housing and low cost of living, McAllen, TX, emerged as a COVID-19 pandemic-era boomtown—but that surge has since reversed.
McAllen—a city of 146,000 people situated just a few miles north of the U.S.-Mexico border—experienced the sharpest decline in popularity among local homebuyers over the past six years, according to a new report from Realtor.com®.
Advertisement
The report analyzed the 100 largest U.S. metros for cross-market demand. Economists looked at views of Realtor.com listings, comparing how many out-of-town visitors were looking at homes in a city versus how many locals were shopping for properties elsewhere between April and June 2025.
According to the latest data, during the spring season, 65% of online home shopping traffic in McAllen went to listings outside the city, representing a 30% increase from 2019—the biggest jump among all the analyzed metros.
Realtor.com economist Jiayi Xu explains that McAllen's drop in homebuyer interest could be attributed to a combination of factors.
Advertisement
3 McAllen—a city of 146,000 people situated just a few miles north of the U.S.-Mexico border—experienced the sharpest decline in popularity among local homebuyers over the past six years.
Courtesy of City of McAllen
'Like many affordable markets, McAllen, TX, attracted new residents during the pandemic due to its low cost of living,' says Xu. 'However, as home prices rose and return-to-office trends resumed, some of that migration has started to reverse.'
Lower affordability, higher unemployment
In June 2025, the median home list price in McAllen was $274,950, up more than 38% from the same period in 2019.
Meanwhile, the unemployment rate in the border city reached 6% in May of this year, compared with 5.4% six years ago.
Advertisement
In light of rising home prices and shrinking job opportunities in McAllen, local homebuyers began casting covetous glances toward more busting nearby metros like Austin and San Antonio, where there is an abundance of high-paying work.
3 According to the latest data, during the spring season, 65% of online home shopping traffic in McAllen went to listings outside the city.
Realtor.com
According to the Realtor.com analysis, McAllen residents' out-of-market online home searches directed at Austin and San Antonio surged from just 4.8% and 16.1%, respectively, to 10.7% and 18.9% over the past six years.
Ironically, McAllen might be a victim of its own success, as rising home equity has likely enabled residents to relocate to higher-priced metros.
Advertisement
'Over the last six years, home prices in McAllen have climbed 65.6% on a price-per-square-foot basis, significantly increasing homeowner equity,' says Realtor.com senior economic research analyst Hannah Jones. 'This equity growth may be providing some local homeowners with the flexibility to pursue employment opportunities in other parts of Texas.'
3 Meanwhile, the unemployment rate in the border city reached 6% in May of this year, compared with 5.4% six years ago.
Google Maps
But according to Jones, it's not all bad news for McAllen, located just across the Rio Grande from Mexico—an area that has been at the center of the ongoing border crisis.
'While the 'border crisis' narrative could nudge some buyers or employers away from McAllen, there is no evidence of a mass exodus of population,' she says. 'The area's housing market remains stable, and its relative affordability means that the area sees strong demand from out-of-metro buyers.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines
As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines

Business Upturn

time35 minutes ago

  • Business Upturn

As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines

St. Paul, MN, Aug. 01, 2025 (GLOBE NEWSWIRE) — Cold chain logistics is one of the fastest-growing industries in the world, projected to top $420 billion this year alone. That surge comes with rising demand for product, speed, and increasingly, gear that can keep up with the conditions. Ergodyne is answering that call with its rapidly expanding cold storage collection. The worksite safety pioneer just launched its warmest freezer jacket to date, new thermal impact gloves, and merino blend socks—rounding out a head-to-toe system for cold storage and sub-zero work. 'We've built this collection directly with the folks who do it, day in and day out,' said Ergodyne Product Manager, Claudia Weber. Weber credits the quick adaption by major players in the cold chain space to her team's relentless focus on what crews really need. 'I think it's resonating because they know it was not only made for them (the workers), but with them, too.' Field testing with real cold storage teams, ongoing feedback loops, and on-site observations ensure every feature is grounded in real-world utility. An easy to miss but impactful example of this process are the exterior sizing labels found on outer layers, which allows for instant ID off the rack. 'Seems like not a huge deal,' said Weber. 'But to the workers sifting through the gear every day to find the right size, it is.' But as cold storage PPE demand heats up, so does confusion around one of the most asked questions in the industry: What do temperature ratings actually mean? 'There's a lot of misinformation—and even more misunderstanding—about what temperature ratings truly represent,' said Ergodyne President, Greg Schrab. 'We're committed to educating our users and helping them make informed decisions based on the best information available, not assumptions.' To that end, Ergodyne has published a guide aimed at demystifying temperature ratings, laying out what they measure, how they're tested, and why context—like activity level and duration of exposure—matters just as much as the rating itself. Read the full piece here. 'Just like any PPE, cold storage crews need the proper information about their thermal gear to make the right choice for their application,' Schrab continued. 'That's why we've always been as serious about education as we are about innovation.' For more information on the latest in Ergodyne's cold storage collection, visit ABOUT ERGODYNE Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters. Originally posted on: Attachment New Cold Storage Gear Solutions Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Miami Herald

time38 minutes ago

  • Miami Herald

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H'2025 - IDE submission for enVVe® on track for 2H'2025 IRVINE, CA / ACCESS Newswire / August 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the second quarter 2025. "As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially debilitating once it becomes severe. Our participation in several of the recent national news stories about CVI fits with our strategy of establishing enVVeno Medical as the world-wide leader in treatments for severe, deep venous disease. With several value driving milestones on the horizon, including FDA decisions on potential approval for the VenoValve and the pivotal study for enVVe, we continue to make strong progress in our mission to bring first-in-category, effective treatments to patients with severe CVI, and are well positioned to lead the ongoing national dialogue about CVI as further events are reported," commented Robert Berman, CEO of enVVeno Medical. Summary of Financial Results for the Second Quarter 2025The Company ended the quarter with $35.1 million in cash and investments. Based on management's current expectations, this capital has the potential to fund the Company through the third quarter of 2026, including pre-commercialization activities for the VenoValve, and the commencement of the enVVe pivotal study. Cash burn for the quarter was $3.8 million, consistent with the Company's projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins. The Company reported net losses of $6.7 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, representing an increase in net loss of $1.7 million, or 35%. This increase was primarily due to higher operating expenses of $1.6 million resulting from additional personnel costs, the issuance of option grants, and non-recurring reserve and severance expenses, as well as a decrease in other income of $0.1 million. Clinical Program ProgressVenoValve®: Novel, First-In-Class Surgical Replacement Venous Valve Amended VenoValve PMA application in response to formal questions from U.S. Food and Drug Administration (FDA)Continue to respond to FDA questions and inquiries as they arisePresented positive interm, two-year data at Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingPMA decision from FDA expected 2H'2025 enVVe®: Novel, First-In-Class Non-Surgical Transcatheter-Based Replacement Venous Valve Successfully completed final wave for the shorter-term subjects in 6-month pre-clinical GLP studyAwaiting final pathology form the GLP studySuccessfully completed other testing necessary for IDE filingIDE filing for enVVe pivotal trial on track for 2H'2025 President Trump CVI DiagnosisFollowing President Trump's recent diagnosis of what appears to be moderate CVI, Dr. Marc Glickman, Senior Vice President and Chief Medical Officer of enVVeno Medical was featured in several national television news segments, podcasts, radio reports, and news articles, including Fox News, NewsMax, Morning Wire, and the N.Y. Post. To view this media, click here. About enVVeno Medical CorporationenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking StatementsThis press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. ### INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation

As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines
As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines

Yahoo

timean hour ago

  • Yahoo

As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines

New Cold Storage Gear Solutions St. Paul, MN, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Cold chain logistics is one of the fastest-growing industries in the world, projected to top $420 billion this year alone. That surge comes with rising demand for product, speed, and increasingly, gear that can keep up with the conditions. Ergodyne is answering that call with its rapidly expanding cold storage collection. The worksite safety pioneer just launched its warmest freezer jacket to date, new thermal impact gloves, and merino blend socks—rounding out a head-to-toe system for cold storage and sub-zero work. 'We've built this collection directly with the folks who do it, day in and day out,' said Ergodyne Product Manager, Claudia Weber. Weber credits the quick adaption by major players in the cold chain space to her team's relentless focus on what crews really need. 'I think it's resonating because they know it was not only made for them (the workers), but with them, too.' Field testing with real cold storage teams, ongoing feedback loops, and on-site observations ensure every feature is grounded in real-world utility. An easy to miss but impactful example of this process are the exterior sizing labels found on outer layers, which allows for instant ID off the rack. 'Seems like not a huge deal,' said Weber. 'But to the workers sifting through the gear every day to find the right size, it is.' But as cold storage PPE demand heats up, so does confusion around one of the most asked questions in the industry: What do temperature ratings actually mean? "There's a lot of misinformation—and even more misunderstanding—about what temperature ratings truly represent," said Ergodyne President, Greg Schrab. 'We're committed to educating our users and helping them make informed decisions based on the best information available, not assumptions.' To that end, Ergodyne has published a guide aimed at demystifying temperature ratings, laying out what they measure, how they're tested, and why context—like activity level and duration of exposure—matters just as much as the rating itself. Read the full piece here. 'Just like any PPE, cold storage crews need the proper information about their thermal gear to make the right choice for their application,' Schrab continued. 'That's why we've always been as serious about education as we are about innovation.' For more information on the latest in Ergodyne's cold storage collection, visit ABOUT ERGODYNE Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters. Originally posted on: Attachment New Cold Storage Gear Solutions CONTACT: Ergodyne 8002258238 tenaciousnation@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store